^
Association details:
| Biomarker: | CDH2 underexpression |
|---|---|
| Cancer: | Glioma |
| Drug: | temozolomide (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CDH2 expression is of prognostic significance in glioma and predicts the efficacy of temozolomide therapy in patients with glioblastoma
Excerpt:
Patients with low CDH2 expression had an improved prognosis and benefited from temozolomide therapy. In conclusion, these findings revealed that CDH2 may serve as a prognostic and predictive molecular biomarker for the grading and treatment of glioma.
Secondary therapy:
paclitaxel + carboplatin
DOI:
10.3892/ol.2018.8227
